<DOC>
	<DOCNO>NCT02381730</DOCNO>
	<brief_summary>Polypoidal choroidal vasculopathy ( PCV ) disease choroidal vasculature , often regard sub-type age-related macular degeneration ( AMD ) . However , PCV response anti-vascular agent differs response typical AMD . This study aim describe evolution best correct visual acuity ( BCVA ) PCV patient , 28 week receive one injection intravitreal aflibercept ( 2mg ) .</brief_summary>
	<brief_title>Assessment Visual Acuity Patients With Polypoidal Choroidal Vasculopathy Aflibercept Treatment</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Active polypoidal choroidal vasculopathy , Visual acuity superior 1/10 ( 20/200 ) inferior 6,25/10 ( 20/32 ) Age 45 No prior intravitreal treatment , response prior treatment 3 injection ranibizumab , disease recurrence 3 month stability Intravitreal injection aflibercept indicated current clinical recommendation Simultaneous treatment another antiVEGM agent Diabetic retinopathy Personal history vitrectomy uveitis Personal history laser photocoagulation and/or verteporphin phototherapy Tear pigmentary epithelium Chorioretinitis scar Macular atrophy pigmentary epithelium Treatment corticosteroid Eye surgery le 3 month inclusion</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>